Past Articles

Employers Could See Big Savings With Semglee

Some good news has finally been announced for one high priced insulin product. Semglee (manufactured by Biocon Biologic and Mylan) is a new long-acting insulin product that was recently approved by the FDA in June. Semglee is similar to Lantus (manufactured by Sanofi-Aventis) which is a highly prescribed insulin product. Semglee has been released with an average wholesale price (AWP) of around 65% less than Lantus.


Semglee vs Lantus AWP Comparison


Currently, a prescriber would have to write the prescription for Semglee instead of Lantus, but based on a recent drug trial, Semglee has shown the same safety and efficacy when alternating between Lantus and Semglee, which likely will lead to an FDA approved interchangeability status. This would allow Semglee to be substituted for a prescription written for Lantus. An employer with around 6 utilizing members could see savings of more than $20,000 per year, as a result of this FDA approval.









APC Insights

Copyright © Action Pharmaceutical Consulting. All Rights Reserved

Privacy Policy